# Vosoritide (Voxzogo)

> C-type natriuretic peptide analog for achondroplasia.

Source: https://peptides.cafe/peptide/vosoritide
Category: CNP Analog · Skeletal Growth
Tag: FDA-Approved · Genetic

## Mechanism
Modified C-type natriuretic peptide (CNP) analog that binds NPR-B, antagonizing overactive FGFR3 signaling in the growth plate to increase endochondral bone growth in children with achondroplasia.

## Research areas
- Achondroplasia in children ≥5 years (now ≥4 months)

## Common research protocols
- Daily SC: Weight-based daily subcutaneous injection.

## Study summaries
- "Vosoritide Phase 3 trial" — Lancet (2020): Increased annualized growth velocity vs placebo in children with achondroplasia.

## Considerations
- FDA-approved.
- Transient blood pressure decrease; ensure adequate hydration/food before dosing.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.